Title : Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer.

Pub. Date : 2019 Jan

PMID : 30365094






8 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. osimertinib epidermal growth factor receptor Homo sapiens
2 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
3 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
4 Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
5 The present study investigated treatment with osimertinib combined with IR in EGFR T790M non-small cell lung cancer (NCI-H1975) in vitro and in vivo. osimertinib epidermal growth factor receptor Homo sapiens
6 Furthermore, osimertinib alone or in combination with IR, blocked the phosphorylation of EGFR (Tyr1068/Tyr1173), protein kinase B and extracellular signal-regulated kinase. osimertinib epidermal growth factor receptor Homo sapiens
7 The results of the present study indicated that osimertinib has therapeutic potential as a radiation-sensitizer in lung cancer cells harboring the EGFR T790M mutation, providing a rationale for clinically combining osimertinib with irradiation in EGFR T790M non-small cell lung cancer. osimertinib epidermal growth factor receptor Homo sapiens
8 The results of the present study indicated that osimertinib has therapeutic potential as a radiation-sensitizer in lung cancer cells harboring the EGFR T790M mutation, providing a rationale for clinically combining osimertinib with irradiation in EGFR T790M non-small cell lung cancer. osimertinib epidermal growth factor receptor Homo sapiens